Research

*November 2022* Sunvozertinib (DZD9008) has demonstrated activity in patients with non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation across mutation types and prior treatments, according to data pooled from 3 phase 1/2 clinical trials. Findings from the clinical trials were presented at the International Associationfor the Study of…

*November 2022* Read more.

*November 2022* Never smokers represent a subgroup of patients with advanced lung cancer whose genetic makeup necessitates the need for targeted therapies and clinical trials aimed at improving outcomes. Compared with smokers, defined as those who smoke over 100 cigarettes in their life, never smokers have associated germline mutations for…

*December 2022* Jill Feldman, EGFR Resisters Co-Founder As someone who has been fighting lung cancer indirectly and directly for almost 40 years, I have witnessed and celebrated the rapidly changing landscape of lung cancer diagnosis and treatment. After losing 2 grandparents and my dad to lung cancer when I was…

*November 2022* Osimertinib (Tagrisso) remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer (NSCLC), Zosia Piotrowska, MD, MHS, told her audience at the 17th Annual New York Lung Cancers Symposium®.1 However, for those with classic EGFR mutations, exon 19 deletions and L858R substitutions, she believes the…

*October 2022* There was a focus on treating EGFR-positive NSCLC that has progressed after being treated with currently approved EGFR targeted therapies, with several presentations of new drug combinations and new EGFR targeted therapies. Data from the CHRYSALIS-2 trial was presented looking at giving a combination of the new EGFR…

*October 2022* During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation. Read more.

*October 2022* RESULTS: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all…